Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LipoKnoxa™ Human ACLY shRNA AAV Particle (Silencing)
Cat. No.:
V0126XX402
Species:
Human
Target Gene:
ACLY
Vector System:
AAV
Modulation Type:
Silencing (shRNA)
SPECIFIC INQUIRY
Add to basket
| Sub Cat. No. | AAV Serotype | Tissue Tropism | TargetSeq | Region | Inquiry |
|---|---|---|---|---|---|
| V0126XX402-1 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-2 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-3 | AAV1 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Skeletal muscle; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-4 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-5 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-6 | AAV2 | CNS; Brain; Retina; Inner ear; Kidney; Testes; Liver; Pancreas; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-7 | AAV3 | Lung; Liver; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-8 | AAV3 | Lung; Liver; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-9 | AAV3 | Lung; Liver; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-10 | AAV4 | CNS; Retina; Heart; Lung; Kidney | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-11 | AAV4 | CNS; Retina; Heart; Lung; Kidney | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-12 | AAV4 | CNS; Retina; Heart; Lung; Kidney | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-13 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-14 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-15 | AAV5 | CNS; Brain; Retina; Heart; Lung; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-16 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-17 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-18 | AAV6 | Heart; Lung; Liver; Pancreas; Adipose; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-19 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-20 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-21 | AAV7 | CNS; Brain; Retina; Liver; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-22 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-23 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-24 | AAV8 | CNS; Brain; Retina; Inner ear; Heart; Liver; Pancreas; Kidney; Adipose; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-25 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | GCCTCAAGATACTATACATTT | 3' UTR | Inquiry |
| V0126XX402-26 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | CGTGAGAGCAATTCGAGATTA | CDS | Inquiry |
| V0126XX402-27 | AAV9 | CNS; Brain; Retina; Inner ear; Heart; Lung; Liver; Pancreas; Kidney; Testes; Adipose; Skeletal muscle; Smooth muscle | CCTATGACTATGCCAAGACTA | CDS | Inquiry |
| V0126XX402-28 | Other | Inquiry |
Product Overview
Description:
LipoKnoxa™ Human ACLY shRNA AAV Particle (Silencing) targets ACLY, the link between glucose metabolism and de novo lipogenesis. Engineered with both U6 and miR30-based shRNA frameworks, this tool allows for the exploration of fatty acid and cholesterol synthesis. Our system provides multiple AAV serotypes for tissue-specific tropism, supported by total quality control screening for functional titer, sequence verification, and the absence of pathogens.
Production Cell Line:
HEK293
AAV ITR:
AAV2 ITR
Promoter:
U6; CMV; EF1α; CAG; UBC
Product Availability:
Produced Upon Order
Specification
Titer Test:
qPCR
Insert Verification:
The sequence identity and genomic integrity of all preparations were successfully confirmed via sequencing and PCR validation.
Sterility Test:
Stringent QC assays have verified the sterility of this product lot, ensuring it is free of all detectable microbial contaminants.
Mycoplasma Test:
Confirmed free of mycoplasma contamination via high-sensitivity QC assays; this product lot has successfully passed the production safety protocols.
Other QC:
Tailored supplementary testing and transduction performance assays are available to evaluate gene silencing at the molecular level. We provide comprehensive in vitro and in vivo assessments to elucidate the impact of shRNA-targeted editing on gene expression profiles and downstream biological phenotypes.
Storage:
To maintain optimal viral potency and structural integrity, it is essential to store the vector at -80°C immediately following its receipt.
Stability:
Long-term storage at -80°C ensures product integrity for up to 24 months. For immediate experimental use, the thawed viral preparations are refrigerated at 4°C, maintaining robust performance for a period of 2–3 weeks.
Shipping Condition:
Shipped on dry ice. Product integrity is guaranteed through temperature-controlled logistics for all viral vector types.
Handling Notes:
To prevent titer loss caused by repeated freeze-thaw cycles, we recommend aliquoting the virus into single-use volumes upon receipt. Use low-protein-binding microcentrifuge tubes and store under specified conditions. Strict adherence to biosafety protocols is required; perform all handling within a designated biosafety cabinet.
Intended Use:
This product is intended for research use only and is not for use in diagnosis or therapeutic applications.
Product Disclaimer:
All products undergo stringent quality control; however, no warranty is provided for performance in specific applications, given the diversity of experimental variables. The user is ultimately responsible for ensuring proper storage, handling, and adherence to all local laws, biosafety standards, and safety regulations throughout the use of the product.
Target Profile
Gene Name:
ACLY
Full Name:
ATP citrate lyase
Gene Symbol:
ACL; ATPCL; CLATP
Gene ID:
47
RefSeq ID-1:
NP_001087.2
RefSeq ID-2:
NM_001096.2
Summary:
ACLY encodes ATP citrate lyase, a cytosolic enzyme that generates acetyl-CoA from citrate and coenzyme A through an ATP-dependent reaction. The enzyme functions as a tetramer composed of four similar subunits and produces acetyl-CoA and oxaloacetate while hydrolyzing ATP to ADP and phosphate. Acetyl-CoA derived from ACLY serves as a key precursor for lipid and cholesterol biosynthesis, pathways that are frequently upregulated in obesity and metabolic syndrome. Increased ACLY activity supports de novo lipogenesis in adipose tissue and liver, contributing to fat accumulation. In neuronal tissues, ACLY may also participate in acetylcholine synthesis. Multiple transcript variants encoding distinct isoforms have been described.